Dr. Ralf Brandt
Dr. Ralf BrandtPresident, Discovery and Early Development

Dr. Ralf Brandt (PhD)

President, Discovery and Early Development

Dr. Brandt is the co-founder of vivoPharm. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes. During Dr. Brandt’s long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada and Propanc in Melbourne VIC, Australia.

Dr. Glenn J. Smits
Dr. Glenn J. SmitsSenior Vice President, Discovery and Early Development

Dr. Glenn J. Smits

Senior Vice President, Discovery and Early Development

Dr. Smits joined vivoPharm in 2013 as Director of Business Development and Marketing and became Vice President of Pharmacology and Toxicology in 2015.  Upon the acquisition of vivoPharm by Cancer Genetics Inc, Dr. Smits was promoted to the role of Senior Vice President, Discovery and Early Development. He was previously Vice President and General Manager of the Discovery Sciences division of MPI Research, where he was responsible for the strategic direction, growth, and performance of the division, consisting of the departments of Drug Metabolism/Pharmacokinetics, Experimental Therapeutics, Surgical Services, Molecular and Cellular Biology, and Molecular Imaging.  As Scientific Director of the Interventional and Surgical Services business unit at Charles River Laboratories, Glenn directed the execution and quality of the scientific research within the unit. In addition to his extensive experience in the CRO industry, he has spent over 15 years in biopharmaceutical R&D, holding various senior management and scientific management positions at Genome Therapeutics, Biogen, Rhone-Poulenc Rorer (now part of Sanofi-Aventis), and Searle R&D (now part of Pfizer).  Dr. Smits has a BS in Biology from Marquette University, a MS in Pharmacology from the Medical College of Wisconsin, and a PhD in Pharmacology from St. Louis University School of Medicine.

Mrs. Sabine Brandt
Mrs. Sabine BrandtExecutive Finance & HR Manager

Mrs. Sabine Brandt

Executive Finance & HR Manager

Mrs Sabine Brandt is a co-founder of vivoPharm. Her career, which has spanned close to 10 years, includes financial management, financial planning and sales in a variety of industry sectors such as insurance and banking. In these roles, Mrs Brandt has gained experience within various departments of the banking and financial markets in Germany. Mrs Brandt led in the establishment of new offices for some insurance companies which has brought her a high level of experience in accounting and sales.

Mr. Chris Holding
Mr. Chris HoldingDivision Head, Efficacy Testing

Mr. Chris Holding

Division Head, Efficacy Testing

Chris’s experience in both the running of studies from a project management position, as well extensive experience in performing the technical elements of in vitro and in vivo studies offered by vivoPharm enables him to be critically involved throughout the design, execution and reporting phase of the studies, as required.

Initially responsible for Study Co-ordination at vivoPharm’s Australian facility in 2009, Chris Holding relocated to the US in July of 2011 to translate vivoPharm’s quality of service at the newly established site in Hershey, Pennsylvania. After building the technical teams for all in vitro and in vivo studies in his first year, Chris’s current role as Group Leader in vivo Pharmacology is to over see the running of all studies by vivoPharm’s Study Co-ordinators at the US facility. Additionally, Chris oversees operations at the US facility and is responsible for ensuring vivoPharm’s commitment to quality, transparency and communication are maintained.

Dr. Melanie Keller
Dr. Melanie KellerDivision Head, Europe

Dr. Melanie Keller

Division Head, Europe

Dr. Keller joined vivoPharm as Project Manager in 2008 from GPC Biotech AG, where she was responsible for management of international clinical trials (phase I-III). In this position at vivoPharm she coordinated preclinical projects for clients in  Europe and U.S. East. In 2011 she was promoted to Team Leader Europe and is now involved in acquisition of new clients, development of strategies and study designs in close cooperation with the clients, as well as overseeing organisation of the study teams and ongoing project performance.

Dr. Keller received her PhD in 2005 from the Department of Pharmacy – Center for Drug Research at the Ludwig-Maximilian-University Munich, Germany. Subsequently, she took a position as Clinical Research Associate at Ecron (now Ecron Acunova), a full service CRO, where she was responsible for preparation, monitoring and performance of clinical trials (phase II and III).

vivoPharm HQ • Level 3 Office 29 • 240 Plenty Road • Bundoora VIC 3083 Australia

Contact Us

Copyright © 2020 vivoPharm Pty. Ltd.